DOP2013000116A - COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO - Google Patents
COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILOInfo
- Publication number
- DOP2013000116A DOP2013000116A DO2013000116A DO2013000116A DOP2013000116A DO P2013000116 A DOP2013000116 A DO P2013000116A DO 2013000116 A DO2013000116 A DO 2013000116A DO 2013000116 A DO2013000116 A DO 2013000116A DO P2013000116 A DOP2013000116 A DO P2013000116A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- piridin
- ilo
- compounds
- oxazol
- oxazol compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
La presente invención se refiere a compuestos de oxazolo[5,4-b]piridin-5-ilo útiles en el tratamiento de cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382329 | 2010-12-03 | ||
US201161439151P | 2011-02-03 | 2011-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2013000116A true DOP2013000116A (es) | 2014-10-31 |
Family
ID=46162794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2013000116A DOP2013000116A (es) | 2010-12-03 | 2013-05-27 | COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO |
Country Status (26)
Country | Link |
---|---|
US (1) | US8288548B2 (es) |
EP (1) | EP2646445B1 (es) |
JP (1) | JP5726321B2 (es) |
KR (1) | KR101514162B1 (es) |
CN (1) | CN103221415B (es) |
AR (1) | AR083868A1 (es) |
AU (1) | AU2011337033A1 (es) |
BR (1) | BR112013013282A2 (es) |
CA (1) | CA2819822C (es) |
CL (1) | CL2013001518A1 (es) |
CO (1) | CO6761387A2 (es) |
CR (1) | CR20130182A (es) |
DO (1) | DOP2013000116A (es) |
EA (1) | EA021241B1 (es) |
EC (1) | ECSP13012653A (es) |
ES (1) | ES2567271T3 (es) |
GT (1) | GT201300139A (es) |
IL (1) | IL226054A0 (es) |
MX (1) | MX2013006184A (es) |
NZ (1) | NZ610289A (es) |
PE (1) | PE20140008A1 (es) |
SG (1) | SG190680A1 (es) |
TW (1) | TWI410425B (es) |
UA (1) | UA109677C2 (es) |
WO (1) | WO2012074761A1 (es) |
ZA (1) | ZA201303580B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102279347B1 (ko) | 2016-12-15 | 2021-07-21 | 한국생명공학연구원 | 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물 |
PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ520640A (en) | 2000-02-15 | 2005-04-29 | Upjohn Co | Pyrrole substituted 2-indolinone protein kinase inhibitors |
AR029803A1 (es) * | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
CA2440211A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
DE60309342T2 (de) * | 2002-08-09 | 2007-05-16 | Eli Lilly And Co., Indianapolis | Benzimidazole und benzothiazole als inhibitoren der map-kinase |
TWI332003B (en) * | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
EP1781293A1 (en) | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
WO2009017822A2 (en) | 2007-08-02 | 2009-02-05 | Amgen Inc. | Pi3 kinase modulators and methods of use |
-
2011
- 2011-11-14 TW TW100141464A patent/TWI410425B/zh not_active IP Right Cessation
- 2011-11-14 AR ARP110104244A patent/AR083868A1/es unknown
- 2011-11-17 UA UAA201306158A patent/UA109677C2/ru unknown
- 2011-11-17 JP JP2013542030A patent/JP5726321B2/ja not_active Expired - Fee Related
- 2011-11-17 SG SG2013034749A patent/SG190680A1/en unknown
- 2011-11-17 US US13/298,319 patent/US8288548B2/en not_active Expired - Fee Related
- 2011-11-17 WO PCT/US2011/061099 patent/WO2012074761A1/en active Application Filing
- 2011-11-17 CA CA2819822A patent/CA2819822C/en not_active Expired - Fee Related
- 2011-11-17 EA EA201390620A patent/EA021241B1/ru not_active IP Right Cessation
- 2011-11-17 BR BR112013013282A patent/BR112013013282A2/pt not_active IP Right Cessation
- 2011-11-17 EP EP11791146.1A patent/EP2646445B1/en not_active Not-in-force
- 2011-11-17 PE PE2013001339A patent/PE20140008A1/es not_active Application Discontinuation
- 2011-11-17 MX MX2013006184A patent/MX2013006184A/es not_active Application Discontinuation
- 2011-11-17 ES ES11791146.1T patent/ES2567271T3/es active Active
- 2011-11-17 NZ NZ610289A patent/NZ610289A/en not_active IP Right Cessation
- 2011-11-17 KR KR1020137014068A patent/KR101514162B1/ko not_active IP Right Cessation
- 2011-11-17 AU AU2011337033A patent/AU2011337033A1/en not_active Abandoned
- 2011-11-17 CN CN201180058009.2A patent/CN103221415B/zh not_active Expired - Fee Related
-
2013
- 2013-04-25 CR CR20130182A patent/CR20130182A/es unknown
- 2013-04-29 IL IL226054A patent/IL226054A0/en unknown
- 2013-05-16 ZA ZA2013/03580A patent/ZA201303580B/en unknown
- 2013-05-27 DO DO2013000116A patent/DOP2013000116A/es unknown
- 2013-05-28 GT GT201300139A patent/GT201300139A/es unknown
- 2013-05-29 CL CL2013001518A patent/CL2013001518A1/es unknown
- 2013-05-31 EC ECSP13012653 patent/ECSP13012653A/es unknown
- 2013-06-11 CO CO13139854A patent/CO6761387A2/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
ES2567271T3 (es) | 2016-04-21 |
IL226054A0 (en) | 2013-06-27 |
GT201300139A (es) | 2014-04-08 |
SG190680A1 (en) | 2013-07-31 |
WO2012074761A1 (en) | 2012-06-07 |
ECSP13012653A (es) | 2013-08-30 |
ZA201303580B (en) | 2014-12-23 |
EP2646445A1 (en) | 2013-10-09 |
CN103221415A (zh) | 2013-07-24 |
MX2013006184A (es) | 2013-07-15 |
KR20130093140A (ko) | 2013-08-21 |
CL2013001518A1 (es) | 2013-11-04 |
CA2819822A1 (en) | 2012-06-07 |
AR083868A1 (es) | 2013-03-27 |
EP2646445B1 (en) | 2016-03-16 |
CO6761387A2 (es) | 2013-09-30 |
AU2011337033A1 (en) | 2013-07-18 |
JP5726321B2 (ja) | 2015-05-27 |
EA201390620A1 (ru) | 2013-10-30 |
CN103221415B (zh) | 2015-06-17 |
PE20140008A1 (es) | 2014-01-31 |
TW201300397A (zh) | 2013-01-01 |
KR101514162B1 (ko) | 2015-04-21 |
TWI410425B (zh) | 2013-10-01 |
NZ610289A (en) | 2015-07-31 |
JP2013544835A (ja) | 2013-12-19 |
CR20130182A (es) | 2013-07-09 |
US20120142724A1 (en) | 2012-06-07 |
CA2819822C (en) | 2015-07-21 |
EA021241B1 (ru) | 2015-05-29 |
UA109677C2 (ru) | 2015-09-25 |
US8288548B2 (en) | 2012-10-16 |
BR112013013282A2 (pt) | 2016-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110046A (es) | Amidofenoxiindazoles utiles como inhibidores de c-met | |
CL2016001733A1 (es) | Compuestos intermediarios para la preparación de compuestos derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer div. sol. 3415-12. | |
ECSP11011441A (es) | Compuestos vinil indazolilo | |
UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
CR20130539A (es) | Triazolopiridinas | |
AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
BRPI1009118A2 (pt) | 3h-imidazo[4,5-c] piridina-6-carboxamidas como agentes anti-inflamatórios | |
UY34165A (es) | ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?. | |
BRPI0919292A2 (pt) | 3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios | |
CL2012002979A1 (es) | Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona. | |
AU2012213775A8 (en) | 7-azaindole derivatives | |
NI201100155A (es) | Composiciones y métodos para el tratamiento prolongado con aminopiridinas | |
CR20110427A (es) | Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata | |
IL229993A (en) | 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2 | |
EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
CR20130041A (es) | ISOXAZOLO[5,4-b]PIRIDINAS HERBICIDAS | |
UY34349A (es) | OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO | |
DOP2013000116A (es) | COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO | |
ECSP10010721A (es) | Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida | |
BR112013000941A2 (pt) | formulações de 14-epi-análogos de vitamina d | |
CR20130005A (es) | Agentes terapéuticos 976 | |
UY34433A (es) | Compuestos antimicrobianos con carbolina | |
PA8846601A1 (es) | Tratamiento de infecciones bacterianas intracelulares | |
NZ609924A (en) | Porphyrin treatment of neurodegenerative diseases |